koko体育app
肿瘤患者与健康对照人群半胱氨酸蛋白酶抑制剂C水平的比较研究
The Levels of Serum Cystatin C in Patients with Tumors and Healthy Controls
-
摘要: 目的 探讨血清半胱氨酸蛋白酶抑制剂C（cystatin C）浓度水平与肿瘤的关系。 方法 颗粒增强免疫比浊法测定273例实体恶性肿瘤患者（肿瘤组）和185例健康体检者（对照组）的血清cystatin C浓度，比较两组血清cystatin C浓度水平的差异并分析其影响因素。 结果 肿瘤组、对照组cystatin C水平差异无统计学意义（P=0.075）；但去除混杂因素年龄的影响后两者差异有统计学意义（P<0.01）；且多元回归分析显示cystatin C水平对照组比肿瘤组高、男性比女性高，且随年龄增长、肾小球滤过率（eGFR）水平下降而升高。 结论 Cystatin C可能在肿瘤的发生发展中起到一定作用。Abstract: Objective To determine the association between serum cystatin C and tumors. Methods Serum samples were obtained from 273 patients with tumors and 185 healthy volunteers. Serum cystatin C was determined by particle-enhanced turbidimetric immunoassay (PETIA). Student t-test, covariance analysis and multiple linear regressions were performed to examine the differences in the levels of cystatin C between the two groups. Results The student t-test did not show significant statistical differences in the serum cystatin C levels between the two groups (P=0.075). However, such differences became statistically significant (P<0.01) after adjustment of age. The multiple liner regression demonstrated that healthy volunteers and men had higher levels of cystatin C than those with tumors and women. Cystatin C also increased with age and decreases with estimating glomerular filtration rate. Conclusion Cystatin C may be associated with the genesis and development of tumors.
© 2012 《koko体育app
学报（医学版）》编辑部 版权所有
开放获取🐽 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问
下载: